On May 27, 2019, at the invitation of Prof. Hudan Liu,  Prof. Binbing Zhou, the director of the Institute of Pediatric Translational Medicine of Shanghai Jiaotong University Children's Medical Center visited MRI, giving an academic report of Cancer Drug Resistance and Drug Discover: from Checkpoints to Purine Biosynthesis. 

Prof. Binbing Zhou graduated from Fudan University in 1987. He received his Ph.D. in biochemistry from the University of California at Berkeley in 1993. He was a postdoctoral researcher at Harvard Medical School from 1994 to 1998. In 2012, he was selected as an expert in the Central Central Group's Thousand Talents Program. He has long been engaged in research on the mechanism of tumor resistance and overcoming the development of drug-resistant new drugs. He has served as senior director of the Cancer Research Institute of Pfizer Pharmaceuticals, USA, and is responsible for more than 10 anticancer drugs involving small molecules, antibodies and antibody-linked drugs. His current work focuses on the mechanisms of action and application of genetic damage response (DDR) in childhood diseases, including leukemia and stem cell-related diseases. He has published more than 40 SCI papers in internationally renowned journals, including Nature, Nature Medicine, Cancer Cell, Leukemia, etc., and obtained 4 US patents.

After the report, Professor Zhou Binbing had in-depth exchanges and discussions with many professors and graduate students of the Medical Research Institute.  Prof. Zhou expressed their good intentions of mutual cooperation and common development.